GNTA vs. AVRO, CDTX, LENZ, IKNA, ALGS, TSBX, TARA, INAB, ENTX, and ATRA
Should you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include AVROBIO (AVRO), Cidara Therapeutics (CDTX), LENZ Therapeutics (LENZ), Ikena Oncology (IKNA), Aligos Therapeutics (ALGS), Turnstone Biologics (TSBX), Protara Therapeutics (TARA), IN8bio (INAB), Entera Bio (ENTX), and Atara Biotherapeutics (ATRA). These companies are all part of the "biological products, except diagnostic" industry.
AVROBIO (NASDAQ:AVRO) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations.
62.6% of AVROBIO shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 9.2% of AVROBIO shares are held by insiders. Comparatively, 29.0% of Genenta Science shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, AVROBIO had 4 more articles in the media than Genenta Science. MarketBeat recorded 9 mentions for AVROBIO and 5 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.00 beat AVROBIO's score of 0.22 indicating that AVROBIO is being referred to more favorably in the media.
AVROBIO presently has a consensus target price of $2.00, indicating a potential upside of 43.88%. Genenta Science has a consensus target price of $25.00, indicating a potential upside of 686.16%. Given AVROBIO's stronger consensus rating and higher possible upside, analysts plainly believe Genenta Science is more favorable than AVROBIO.
AVROBIO has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.
AVROBIO received 166 more outperform votes than Genenta Science when rated by MarketBeat users. However, 85.71% of users gave Genenta Science an outperform vote while only 66.93% of users gave AVROBIO an outperform vote.
AVROBIO's return on equity of 0.00% beat Genenta Science's return on equity.
Summary
Genenta Science beats AVROBIO on 7 of the 13 factors compared between the two stocks.
Get Genenta Science News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genenta Science Competitors List
Related Companies and Tools
